MedWatch

Forward Pharma self-assured in 'giant rivalry'

Chairman of the Board Florian Schönharting believes that Forward Pharma’s drug candidate to treat psoriasis can topple rivals.

Foto: PR

Denmark-based biotech company Forward Pharma, which is developing a biological drug to treat moderat-to-severe psoriasis, believes that the company’s candidate has a better profile than most of the drugs currently on the market.

The market for psoriasis treatments, which has been focused on ointments for many years, is betting big on biologics now with injectable and oral drugs. Forward Pharma’s candidate is an oral drug with the preliminary name FP187.

Læs hele artiklen

Få 14 dages fri adgang.

Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier